The European Food Safety Agency (EFSA) has formally corrected the misconception that a product’s vegetarian status equates to inherent safety. This scrutiny centers on red yeast rice, a supplement that has been sold for years as a natural remedy for high cholesterol. The concern stems from the supplement’s active compound, monacolin K.
Scientifically, this substance is structurally identical to the prescription medication lovastatin. This similarity raises concerns regarding potential side effects, particularly because the supplement is often consumed without the oversight of a qualified healthcare specialist. Regarding its market status, the associated regulation is anticipated to be officially published in the autumn of 2026.
Following this publication, existing products containing red yeast rice will be permitted to remain on the market for a transitional period, extending until autumn of 2027—a twelve-month window after the regulation takes effect. The structural relationship between the compound found in red yeast rice and established pharmaceuticals necessitates careful consideration for consumers. While marketed as a natural alternative, the biochemical equivalence to a prescribed drug like lovastatin requires consumers to approach its use with caution and, ideally, professional medical guidance to mitigate potential risks.
Topics: #red #yeast #rice
This shows how much more caution is needed when assessing the safety of natural supplements.